

- Hemostasis (*Cont.*):
 endothelium in, 265e-2
 fibrin clot formation, 401
 fibrin clot formation in, 401f
 fibrinolytic system in, 401f, 403
 platelet plug formation in, 400–401
 tests of, 732, 733f
- Hemostatic sealants, 740
- Hemosuccus pancreaticus, 277
- Hemothorax, 1718
- Henbane, 473e-9t
- Henderson-Hasselbalch equation, 315
- Hennekam's syndrome, 1654
- Henoch-Schönlein purpura. *See* IgA vasculitis (Henoch-Schönlein)
- Hensin, 332e-9
- Hepadnaviruses, 214e-2t, 214e-3f. *See also* Hepatitis B virus (HBV)
- Heparan proteoglycans, 402
- Heparan sulfate glycosaminoglycans, 265e-2
- Heparin, 749
 action of, 749–750, 750f
 for acute limb ischemia, 1646
 adverse effects of
 alopecia, 354
 bleeding, 751
 osteoporosis/osteopenia, 752, 2218t
 skin necrosis, 379
 thrombocytopenia. *See* Heparin-induced thrombocytopenia
 transaminase elevation, 752
 in cardiac catheterization, 1461
 coagulation test abnormalities and, 407
 for DIC, 738
 dosage of, 751
 drug interactions of, 44, 103e-10t
 for DVT/PE, 47, 1635, 1635t
 for frostbite, 478e-4
 limitations of, 751, 751t
 vs. low-molecular-weight heparin, 752t. *See also* Low-molecular-weight heparin (LMWH)
 management of
 before endoscopic procedures, 1889t
 before lumbar puncture, 443e-1
 treatment monitoring, 750–751
 monitoring treatment with, 2754t
 for myocardial infarction, 1597, 1598t, 1606
 in parenteral formula, 98e-6
 in PCI, 296e-1
 pharmacology of, 750, 751t
 for thrombophlebitis, 613
 for VTE prophylaxis, 1637t
 for warfarin necrosis, 379
- Heparin-binding proteins, 750
- Heparin-induced thrombocytopenia, 727
 clinical features of, 751, 751t
 delayed onset, 727
 diagnosis of, 727–728, 752
 pathogenesis of, 44
 skin manifestations of, 368
 time course of, 727, 727f
 treatment of, 728, 752, 752t
- Hepatic artery embolization, 567, 2338
- Hepatic encephalopathy. *See* Encephalopathy, hepatic
- Hepatic hydrothorax, 288, 1717
- Hepatic lipase deficiency, familial, 2440t, 2443
- Hepatic necrosis, drug-induced, 43–44
- Hepatic steatosis. *See* Fatty liver disease
- Hepatic stem cells, 453t
- Hepatic vein thrombosis. *See* Budd-Chiari syndrome
- Hepatitis
 acute viral, 2004
 vs. autoimmune hepatitis, 2051
 clinical features of, 283, 2013t, 2015–2016
 complications and sequelae of, 2012, 2018–2019
 diagnosis of
 algorithm for, 2017–2018, 2018t
 liver biopsy, 366e-1f, 366e-6f
 liver function tests, 283, 1998t, 2016
 serologic tests, 2016–2017
 differential diagnosis of, 2019
 etiology of. *See specific hepatitis viruses*
 extrahepatic manifestations of, 2011–2012
 fulminant, 2018
 HIV infection and, 1258
 in military forces, 152e-7
 niacin-associated, 96e-4
 pathogenesis of, 2010–2011
 pathology of, 2012
 prognosis of, 2018
 prophylaxis for, 2020
 risk factors for, 1991
 treatment of, 2020
 alcoholic, 283, 2053, 2053t. *See also* Alcoholic liver disease
 aplastic anemia and, 664
 autoimmune, 2049
 cirrhosis due to, 2060
 clinical features of, 283, 2050–2051
 definition of, 2049
 diagnosis of, 366e-2–3f, 1993t, 2031t, 2050–2051
 differential diagnosis of, 2051
 immunopathogenesis of, 372e-24t, 2049–2050
 prognosis of, 2049
 treatment of, 2051–2052
 type I, 2050
 type II, 2050
 type III, 2050
 chronic, 2031. *See also* Hepatitis B virus (HBV) infection, chronic; Hepatitis C virus (HCV) infection, chronic
 classification of, 2031, 2031t, 2032t
 grading of, 2031, 2032t
 laboratory evaluation of, 2019, 2031t
 staging of, 2031, 2031t
 coagulation disorders in, 739
 drug-induced. *See* Liver disease/failure, drug-induced
 fibrosing cholestatic, 284, 2011, 2074
 fulminant, 2018, 2020
 HSV, 1180
 inflammatory mediators in, 372e-29t
 jaundice in, 283
 neuropathy in, 2685
 physical examination in, 282–283
 radiation, 551
 toxic, 2023, 2025t, 2026t. *See also* Liver disease/failure, drug-induced
 in transplant recipient, 927
 tumor markers in, 473t
- Hepatitis A virus (HAV), 2004–2005, 2005f, 2006t
- Hepatitis A virus (HAV) infection
 clinical features of, 152e-2t, 2005f, 2013t, 2015–2016
 complications and sequelae of, 2018
 diagnosis of, 152e-2t, 1993t, 2005, 2005f, 2016, 2018t
 epidemiology of, 2012, 2013t
 etiology of. *See* Hepatitis A (HAV) virus
 global considerations in, 2012
 incidence pre- and postvaccine, U.S., 785t
 incubation period for, 152e-2t
 in military forces, 152e-2t, 152e-7
 prevention of. *See* Hepatitis A virus (HAV) vaccine
 recurrence of, after liver transplantation, 2074
 risk factors for, 1991
 serology in, 2016
 transmission of, 2012
 treatment of, 2020
- Hepatitis A virus (HAV) vaccine
 for postexposure prophylaxis, 2020–2021
 precautions for, 790t
 recommended administration of
 in adults, 787–788f, 2021, 2021t
 in cancer patients, 485t
 in children, 2021, 2021t
 in HIV infection, 1252t
 in liver disease, 1995, 2021
 in transplant recipients, 929, 929t
 in travelers, 795, 795t
- Hepatitis B core antigen (HBcAg), 2006, 2006t
- Hepatitis B e antigen (HBeAg), 2006, 2006t
- Hepatitis B surface antigen (HBsAg), 2005–2006, 2006t
- Hepatitis B virus (HBV)
 extrahepatic sites of, 2008
 gene expression and replication in, 214e-5
 genomic structure of, 2005, 2005f
 molecular variants of, 2008
 proteins and particles of, 2005–2007, 2005f, 2006t
 serologic and viral markers of, 2007–2008, 2007f, 2008f
 structure of, 214e-2t
- Hepatitis B virus (HBV) infection
 chronic, 2031
 after kidney transplantation, 927, 1831
 cirrhosis due to, 2060
 clinical features of, 2033
 diagnosis of, 366e-2f, 2031t, 2033
 global considerations in, 2060
 HBeAg-negative, 2032–2033, 2035, 2038, 2039t
 HBeAg-reactive, 2032, 2038, 2039t
 HDV infection with, 2014, 2040
 histology of, 2031–2032
 nonreplicative phase, 2032
 prognosis of, 2032
 renal involvement in, 1849
 replicative phase of, 2032
 treatment of, 2033
 adefovir, 215e-4t, 215e-9, 2035, 2037t, 2038f
 combination therapy, 215e-4t, 215e-9, 2037–2038
 entecavir, 215e-4t, 215e-9–10, 2036, 2037t, 2038f
 IFN- α , 2033
 IFN- α 2a, 2036
 IFN- α 2b, 215e-4t, 215e-10, 2035
 lamivudine, 215e-4t, 215e-9, 2034–2035, 2037t, 2038f
 liver transplantation, 2068
 novel antivirals and strategies, 2038
 PEG IFN, 215e-4t, 215e-10, 2035–2036, 2037t, 2038f, 2039, 2040t
 recommendations for, 2038–2040, 2039t, 2040t
 telbivudine, 215e-4t, 215e-10, 2036, 2037t, 2038f
 tenofovir, 215e-4t, 215e-9, 2037, 2037t, 2038f
 clinical features of, 152e-2t, 2013t, 2015–2016
 cholestasis, 284
 polyarteritis nodosa, 2187
 rash, 132t, 135
 serum sickness–like, 837
 time course of, 2007f
 complications and sequelae of, 2018–2019
 diagnosis of, 2016
 algorithm for, 2017–2018, 2018t
 laboratory tests in, 1993t
 quantitative nucleic acid test in, 150e-7–8
 serology in, 152e-2t, 2007–2008, 2008f, 2016–2017, 2017t, 2018t
 epidemiology of, 2012–2014, 2013t
 escape mutants in, 2008
 etiology of. *See* Hepatitis B virus (HBV)
 extrahepatic manifestations of, 2011–2012
 genotypes in, 2005–2006
 global considerations in, 2013–2014
 HDV infection with, 2009, 2011, 2039
 in health care workers, 1284
 hepatocellular carcinoma and, 214e-7, 544, 545t
 HIV infection and, 1258, 1273, 2030
 incidence of, 785t, 869
 incubation period for, 152e-2t
 in military forces, 152e-2t, 152e-7
 pathogenesis of, 2010–2011
 in pregnancy, 49
 prevention of, 152e-2t, 1284. *See also* Hepatitis B virus (HBV) vaccine
 prognosis of, 2018